Trial Profile
A Phase 2A, Randomized, Double-blind, Placebo-controlled, Single Dose, Sequential Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 With Ticagrelor Pretreatment in Older and Elderly Subjects and With High-Dose Ticagrelor Pretreatment in Healthy Younger Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Bentracimab (Primary) ; Ticagrelor
- Indications Haemorrhage
- Focus Adverse reactions; Pharmacodynamics
- Sponsors PhaseBio Pharmaceuticals
- 21 Nov 2019 According to a PhaseBio Pharmaceuticals media release, the company will present full PB2452 Phase 2a results in 1H 2020
- 24 Sep 2019 Status changed from recruiting to completed, according to a PhaseBio Pharmaceuticals media release.
- 17 Jun 2019 According to a PhaseBio Pharmaceuticals media release, the company expects to report full results from the trial at an upcoming medical congress.